Seres Therapeutics, Inc. (MCRB)
Develops living bacterial treatments to restore gut health and prevent infections in transplant and liver disease patients.
$4.80-0.01%Healthcare
StockGlow Score
Bearish
BearishBullish
1 year ago-65.7%
The outlook
MCRB is trading near its 52-week lows, well below both its 50- and 200-day moving averages, reflecting a weak near-term trend. The overall StockGlow score shows bearish sentiment, though analysts' average price target sits substantially above the current level. The stock remains thinly positioned in its yearly range.
What’s behind the score
Price trendBelow its 50- & 200-day averages
52-week range1% of the way from its 52-week low to high
Price targetAvg target +254% vs current price
Analyst price target
~12-month · 2 analysts$17.00average target+254.2% vs now
Now $4.80
Low $12.00High $22.00
Published targets from Wall Street analysts (public data) — what analysts expect over roughly a year. This is not a StockGlow forecast and not a recommendation. Analyst targets are frequently wrong.
Market cap
$46.5M
52-wk high
$29.98
52-wk low
$4.59
50-day avg
$6.70
200-day avg
$11.54
Trailing P/E
—